BRAF and melanoma: The oncogene HRAS, rather than NRAS and KRAS, is mutated in cSCCs [100], particularly in cSCCs occurring in melanoma patients treated with BRAF inhibitors (3–20%) [101,102], and it promotes the upregulation of downstream MAPK and PI3K/AKT/mTOR signaling.